20 April, 2016 by The TZ Newswire Staff Comments Off on Ad hoc: MorphoSys Provides Update on Results From Partner’s Phase 2b/3 RESILIENT Study of Bimagrumab
Ad hoc: MorphoSys Provides Update on Results From Partner’s Phase 2b/3 RESILIENT Study of Bimagrumab
20 April, 2016 by The TZ Newswire Staff Comments Off on Switzerland trade balance March +CHF2.16 bln vs +CHF4.02 bln prev
Switzerland trade balance March +CHF2.16 bln vs +CHF4.02 bln prev
Latest Swiss trade data now out 21 April
– prev revised down from +CHF 4.07bln
– exports real mm -1.1% vs +2.1% prev revised down from +2.8%
– imports real mm +9.3% vs -1.5% prev revised up from -2.0%
Switzerland sucking in some imports supporting yesterday’s perky ZEW investor sentiment reading.
20 April, 2016 by The TZ Newswire Staff Comments Off on AUDUSD orders 21 April
AUDUSD orders 21 April
Currently 0.7812 looking perky but resistance/offers still to break nearby
Offers: 0.7825-30 0.7850 0.7880 0.7900 (strong – barrier option) 0.7930 0.7950
20 April, 2016 by The TZ Newswire Staff Comments Off on EURJPY orders 21 April
EURJPY orders 21 April
Currently 123.79 also near Asian lows as yen demand returns
ECB the scheduled risk event at 11.45 and 12.30 GMT. Yen risk-plays on-going.
Offers: 124.00-10 124.30 124.50 124.75 125.00 125.30 125.50 125.75 126.00
20 April, 2016 by The TZ Newswire Staff Comments Off on Currencies: Dollar drifts lower against yen; ECB meeting in the spotlight
Currencies: Dollar drifts lower against yen; ECB meeting in the spotlight
The U.S. currency was tracking its overnight strength after upbeat U.S. housing data.
20 April, 2016 by The TZ Newswire Staff Comments Off on USDJPY orders 21 April
USDJPY orders 21 April
Currently 109.60 back down near Asian lows
Bids nearby and good offers into 110.00 still.
Offers: 109.80-85 110.00 (strong) 110.20 110.50 110.65 110.80 111.00
20 April, 2016 by The TZ Newswire Staff Comments Off on Novartis hit by patent expiries, eyecare struggles
Novartis hit by patent expiries, eyecare struggles
Novartis said first-quarter core net income fell 13 percent as it continues to suffer from patent expiries and a struggling eyecare business.